MMP9 and colitis: Therapeutic dosing of AB0046 in a DSS-induced colitis model of UC showed that inhibiting MMP9 after disease was established significantly improved multiple disease parameters, including histopathology and the clinically relevant metrics of body weight loss, diarrhea, and endoscopic disease.